Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Melanoma research - 1 Aug 2014

Lebbé Celeste, How-Kit Alexandre, Battistella Maxime, Sadoux Aurelie, Podgorniak Marie-Pierre, Sidina Irina, Pages Cécile, Roux Jennifer, Porcher Raphael, Tost Jorg, Mourah Samia

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Indoles
Share to Melanoma
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 24933605
DOI: 10.1097/CMR.0000000000000088

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.PMID 24933605Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.Semantic proximity Read ↗

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.Semantic proximity Read ↗

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.